MedTrace Logo

Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

NCT06060652 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2023-09-29

No results posted yet for this study

Summary

Currently, despite the advent of next-generation imaging has improved the detection of Oligometastatic prostate cancer (OMPC), prognostic biomarkers able to stratify patients and monitor treatment response are lacking and urgently needed. Mounting evidence suggests that molecular profiling of the disease and host immune activity evaluation can reveal OMPC heterogeneity and address the above unmet clinical need.

This study aims at combining the analysis of several biomarkers to improve the prognostic stratification of OMPC patients

Conditions

Sponsors & Collaborators

  • Centro di Riferimento Oncologico - Aviano

    lead OTHER

Principal Investigators

  • Fabio Matrone, MD · Centro di Riferimento Oncologico (CRO), IRCCS

  • Giulia Brisotto, PhD · Centro di Riferimento Oncologico di Aviano (CRO)

  • Matteo Turetta, MD · Centro di Riferimento Oncologico di Aviano (CRO)

  • Fabio Del Ben, MD · Centro di Riferimento Oncologico di Aviano (CRO)

  • Luca Triggiani, MD · Asst Degli Spedali Civili Di Brescia

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-11
Primary Completion
2026-05-11
Completion
2026-05-11

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060652 on ClinicalTrials.gov